Supraventricular tachycardia after withdrawal of prolonged dexmedetomidine infusion in a paediatric patient without heart disease
- 27 May 2017
- journal article
- case report
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 42 (5) , 653-655
Abstract
Summary What is known and objective Dexmedetomidine (DEX) has been reported to be safe in paediatric patients. Case description We present the case of a girl without heart disease admitted at our PICU due to an influenza A acute respiratory distress syndrome, who suffered a paroxysmal supraventricular tachycardia (PSVT) twelve hours after DEX progressive withdrawal was completed. What is new and Conclusion This is the first report of PSVT as an adverse reaction to DEX in a paediatric patient without heart disease.Keywords
This publication has 7 references indexed in Scilit:
- Prolonged infusion of dexmedetomidine in critically-ill childrenIndian Pediatrics, 2016
- Dexmedetomidine: review, update, and future considerations of paediatric perioperative and periprocedural applications and limitationsBritish Journal of Anaesthesia, 2015
- Safety and efficacy of prolonged dexmedetomidine use in critically ill children with heart disease*Pediatric Critical Care Medicine, 2012
- Two cases of acute dexmedetomidine withdrawal syndrome following prolonged infusion in the intensive care unitHuman & Experimental Toxicology, 2012
- Cardiovascular Effects of Dexmedetomidine Sedation in ChildrenAnesthesia & Analgesia, 2012
- Discontinuation of prolonged infusions of dexmedetomidine in critically ill children with heart diseaseIntensive Care Medicine, 2011
- Perioperative Use of Dexmedetomidine Is Associated With Decreased Incidence of Ventricular and Supraventricular Tachyarrhythmias After Congenital Cardiac OperationsThe Annals of Thoracic Surgery, 2011